The genetics of antiplatelet drug resistance

Clinical Genetics

Volumn 75, Issue 1, 2009, Pages 1-18

  Feher, Gergely ^a   Feher, A ^a   Pusch, G ^a   Lupkovics, G ^b   Szapary, L ^a   Papp, E ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Zala County Hospital   (Hungary)

Author keywords

Aspirin; Clopidogrel; Genetical polymorphism; Resistance; Variability

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; FIBRINOGEN RECEPTOR; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN IB ALPHA; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; VERY LATE ACTIVATION ANTIGEN 2;

ANTICOAGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG TREATMENT FAILURE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MULTIDRUG RESISTANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ASPIRIN; BLOOD PLATELETS; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; THROMBOSIS; TICLOPIDINE;

EID: 58149189837     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.01105.x     Document Type: Review

References (85)

1. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997: 78: 611-616.
2. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002: 8: 1227-1234.
3. Ibanez B, Vilahur G, Badimon JJ. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J Suppl 2006: 8: G3-G9.
4. Nieswandt B, Watson SP. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003: 102: 449-461.
5. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischaemic myocardium. Cardiovasc Res 2004: 61: 498-511.
6. Andrews RK, Gardiner EE, Shen Y, Berndt MC. Platelet interactions in thrombosis. IUBMB Life 2004: 56: 13-18.
7. Awtry EH, Loscalzo J. Aspirin. Circulation 2000: 101: 1206-1218.
8. Pereillo JM, Maftouh M, Andrieu A et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002: 30: 1288-1295.
9. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003: 101: 3908-3914.
10. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008: 336: 195-198.
11. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 2007: 154(2): 221-231.
12. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 2006: 27: 647-654.
13. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004: 24: 1980-1987.
14. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007: 115: 2196-2207.
15. Censarek P, Steger G, Paolini C et al. Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting. Thromb Haemost 2007: 98: 1309-1315.
16. Rozalski M, Boncler M, Luzak B, Watala C. Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacol Rep 2005: 57: 1-13.
17. Hillarp A, Palmquist B, Lethagen S, Villoutreix BO, Mattiasson I. Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003: 112: 275-283.
18. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 2003: 73: 122-130.
19. Maree AO, Curtin RJ, Chubb A. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005: 3: 2340-2345.
20. Lepäntalo A, Mikkelsson J, Reséndiz JC et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006: 95: 253-259.
21. Kranzhofer R, Ruef J. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets 2006: 17: 163-169.
22. Li Q, Chen BL, Ozdemir V et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007: 8: 577-586.
23. Gonzalez-Conejero R, Rivera J, Corral J, Acuña C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: Heterogeneous response or aspirin failure? Stroke 2005: 36: 276-280.
24. Takahashi S, Ushida M, Komine R et al. Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008: 121: 509-517.
25. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008: 83: 52-60.
26. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmcol Toxicol 1998: 38: 97-120.
27. Rocca B, Secchiero P, Ciabattoni G et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002: 99: 7634-7639.
28. Zimmermann N, Wenk A, Kim U et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003: 108: 542-547.
29. Censarek P, Freidel K, Udelhoven M et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost 2004: 92: 925-9288.
30. Weber AA, Przytulski B, Schumacher M et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: Induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002: 117: 424-426.
31. Guthikonda S, Lev EI, Patel R et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007: 5: 490-496.
32. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000: 102: 840-845.
33. Frelinger AL 3rd, Furman MI, Linden MD et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation 2006: 113: 2888-2896.
34. Roth GJ. Developing relationships: Arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 1991: 77: 5-19.
35. Sonoda A, Murata M, Ito D et al. Association between platelet glycoprotein Ibalpha genotype and ischemic cerebrovascular disease. Stroke 2000: 31: 493-497.
36. Sperr WR, Huber K, Roden M et al. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 1998: 90: 117-123.
37. Afshar-Kharghan V, Matijevic-Aleksic N, Ahn C, Boerwinkle E, Wu KK, Lopez JA. The variable number of tandem repeat polymorphism of platelet glycoprotein Ibalpha and risk of coronary heart disease. Blood 2004: 103: 963-965.
38. Croft SA, Hampton KK, Daly ME, Steeds RP, Channer KS, Samani NJ. Kozak sequence polymorphism in the platelet GPIbalpha gene is not associated with risk of myocardial infarction. Blood 2000: 95: 2183-2184.
39. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol 1998: 18: 1124-1131.
40. Mikkelsson J, Perola M, Penttila A, Karhunen PJ. Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 2001: 104: 876-880.
41. Fujiwara T, Ikeda M, Esumi K et al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J 2007: 7: 395-403.
42. Cervera A, Tassies D, Obach V, Amaro S, Reverter JC, Chamorro A. The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepresented in patients with recurrent stroke regardless of aspirin therapy. Cerebrovasc Dis 2007: 24: 242-246.
43. Macchi L, Christiaens L, Brabant S et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003: 42: 1115-1119.
44. Su G, Wang Z, Ding Y. Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci 2007: 27: 664-667.
45. Nikolopoulos GK, Tsantes AE, Bagos PG, Travlou A, Vaiopoulos G. Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: A meta-analysis. Thromb Res 2007: 119: 501-510.
46. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J 2002: 143: 76-82.
47. Weiss EJ, Bray PF, Tayback M et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996: 334: 1090-1094.
48. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997: 350: 1217-12199.
49. Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res 1997: 33: 693-697.
50. Mamotte CD, van Bockxmeer FM, Taylor RR. PlA1/A2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998: 82: 13-16.
51. Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000: 110: 965-967.
52. Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999: 353: 982-983.
53. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001: 104: 2666-2672.
54. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005: 149: 675-680.
55. Papp E, Havasi V, Bene J et al. Glycoprotein III/a gene (PlA) polymorphism and acetylsalicylic acid resistance: Is there any correlation? Ann Pharmacother 2005: 39: 1013-1018.
56. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004: 15: 89-93.
57. Papp E, Havasi V, Bene J et al. Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance?: A study in older patients. Drugs Aging 2007: 24: 345-350.
58. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007: 119: 355-360.
59. Di Castelnuovo A, de Gaetano G, Benedetta Donati M, Iacoviello L. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice. Am J Pharmacogenomics 2005: 5: 93-99.
60. Chen Y, Kuehl GE, Bigler J et al. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenet Genomics 2007: 17: 571-519.
61. Léon C, Vial C, Gachet C et al. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost 1999: 81: 775-781.
62. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005: 25: 252-257.
63. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N. P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. J Thromb Haemost 2006: 4: 912-914.
64. Fontana P, Dupont A, Gandrille S et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003: 108: 989-995.
65. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 haplotype is associated with peripheral arterial disease: A case-control study. Circulation 2003: 108: 2971-2973.
66. Ziegler S, Schillinger M, Funk M et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005: 36: 1394-1399.
67. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005: 116: 491-497.
68. Smith SM, Judge HM, Peters G et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006: 17: 250-258.
69. Cuisset T, Frere C, Quilici J et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 2007: 120: 893-899.
70. Bierend A, Rau T, Maas R, Schwedhelm E, Böger RH. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. Br J Clin Pharmacol 2008: 65: 540-547.
71. Lau WC, Gurbel PA, Watkins PB et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004: 109: 166-171.
72. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006: 26: 1895-1900.
73. Suh JW, Koo BK, Zhang SY et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006: 174: 1715-1722.
74. Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006: 108: 2244-2247.
75. Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007: 5: 2429-2436.
76. Frere C, Cuisset T, Morange PE et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008: 101: 1088-1093.
77. Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008: 51: 1925-1934.
78. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008: 121: 463-468.
79. LordkipanidzéM, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007: 28: 1702-1708.
80. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function. Results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation 2007: 115: 3156-3164.
81. Malinin AI, Ong S, Makarov LM, Petukhova EY, Serebruany VL. Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006: 60: 993-1002.
82. Feher G, Koltai K, Alkonyi B et al. Clopidogrel resistance: Role of body mass and concomitant medications. Int J Cardiol 2007: 120: 188-192.
83. Feher G, Koltai K, Papp E et al. Aspirin resistance: Possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging 2006: 23: 559-567.
84. Faraday N, Becker DM, Becker LC. Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 2007: 8: 1413-1425.
85. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schömig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005: 16: 199-204.